Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Arabella S. Stuart et al.
Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.
Article
Immunology
Qian He et al.
Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.
EMERGING MICROBES & INFECTIONS
(2021)
Letter
Hematology
Evangelos Terpos et al.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Immunology
Jakub Swadzba et al.
Summary: This study assessed the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine over a 4-month course, with results showing widespread presence of anti-SARS-CoV-2 S IgG antibodies among participants. Women and COVID-19 convalescents exhibited stronger and more persistent humoral responses, while some naive vaccinees failed to develop IgM response.
Article
Multidisciplinary Sciences
Alexandra J. Spencer et al.
Summary: The study suggests that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine against SARS-CoV-2 in mice leads to higher antibody responses and superior cellular immune responses compared to homologous vaccination regimens.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Astha Thakkar et al.
Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.
Review
Immunology
Antonio Bertoletti et al.
Summary: Virus-specific T cells during SARS-CoV-2 infection can play a dual role in either protection or pathogenesis, highlighting the importance of studying the function of these cells for future therapeutic and preventative strategies.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Xinxue Liu et al.
Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.
Article
Medicine, General & Internal
Alberto M. Borobia et al.
Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.
Editorial Material
Biochemistry & Molecular Biology
Meagan E. Deming et al.
Summary: Recent immunogenicity studies have shown that heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine can induce stronger immune responses compared to the homologous ChAdOx1 vaccine series.
Article
Biochemistry & Molecular Biology
Tina Schmidt et al.
Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Letter
Medicine, General & Internal
Johan Normark et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Lisa Mueller et al.
Summary: The study compared antibody responses to the BNT162b2 COVID-19 vaccine in young vaccinees below 60 and elderly vaccinees over 80. The elderly group had lower antibody titers and a lower frequency of neutralizing antibodies post-vaccination, indicating a potential need for closer monitoring or different vaccination strategies for this population.
CLINICAL INFECTIOUS DISEASES
(2021)
